Coherus Oncology, Inc. (CHRS) vs Inogen, Inc. (INGN)
A side-by-side comparison of Coherus Oncology, Inc. and Inogen, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
INGN
Inogen, Inc.
$5.80HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
Total return — CHRS vs INGN
growth of $100 · dividends reinvested · last 10yCHRS -95.9% (-27.3%/yr)INGN -90.0% (-20.6%/yr)INGN compounded faster over this window
CHRS INGN
CHRS vs INGN: by the numbers
- •CHRS is the larger company ($161M vs $157M market cap).
- •Both run net losses; INGN's is the smaller (-6.94% vs -257.10% net margin).
- •INGN grew revenue faster over the past five years (1.02% vs -33.60% CAGR).
Metrics side by side
Valuation
| Metric | CHRS | INGN |
|---|---|---|
| P/S ratio | 3.17 | 0.44 |
| P/B ratio | 2.65 | 0.90 |
Profitability
| Metric | CHRS | INGN |
|---|---|---|
| Gross margin | 63.55% | 48.89% |
| Operating margin | -425.72% | -8.45% |
| Net margin | -257.10% | -6.94% |
| ROE | -215.26% | -14.07% |
| ROIC | -135.38% | -13.94% |
Growth (annualized)
| Metric | CHRS | INGN |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 1.02% |
| Total return CAGR (5Y) | -41.38% | -32.83% |
Frequently asked
- Which has grown faster, CHRS or INGN?
- Over the past five years, INGN grew revenue faster — CHRS at a -33.60% CAGR versus INGN at 1.02%.
- How have CHRS and INGN total returns compared?
- Over the past 10 years, CHRS delivered -26.92% and INGN delivered -20.74% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.